Effects of Anastrozole Combined with Shuganjiangu Decoction on Osteoblast-like Cell Proliferation, Differentiation and OPG/RANKL mRNA Expression
- Author:
- No author available
- Journal Title:
- Chinese Journal of Cancer Research
- Issue:
- 2
- DOI:
- 10.1007/sl1670-012-0151-6
- Key Word:
- Shuganjiangu decoction;Osteoblast-like cell;Alkaline phosphatase;Osteocalcin;Osteoprotegerin;Receptor activator of nuclear factor kappa B ligand (RANKL)
Abstract： Objective:To investigate the effects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cells.Methods:Human osteoblast-like cells MG-63 were cultured and divided into four groups:control,anastrozole,Shuganjiangu decoction (SGJGD),and anastrozole combined with SGJGD.Cell proliferation was investigated by MTT assay.Alkaline phosphatase (ALP) and osteocalcin,the indicators of cell differentiation,were evaluated by p-nitrophenylphosphate method and radioimmunoassay,respectively.Gene expressions of ALP,osteocalcin,osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) were examined by real-time PCR.Results:As evidenced by MTT assay,cell proliferation of MG-63 was inhibited by anastrozole,but stimulated with treatment of SGJGD alone and combined with anastrozole (P＜0.01).Compared with control group,ALP activity was increased by the treatment of SGJGD alone and combined with anastrozole (P＜0.01).Also,osteocalcin secretion was enhanced with the treatment of SGJGD single and combination with anastrozole (P＜0.05).In the real-time PCR assay,gene expressions of ALP and osteocalcin were significantly increased (P＜0.01 for ALP,P＜0.05 for osteocalcin) by the treatment of SGJGD and anastrozole combined with SGJGD,but the expression of RANKL was decreased (P＜0.05).Moreover,anastrozole combined with SGJGD upregulated gene expression of OPG (P＜0.01).Conclusion:SGJGD may alleviate the injury effects of anastrozole on MG-63 cells through adjusting bone formation and resorption indicators.
- [1]孙红,李萍萍,解云涛.舒肝凉血方与三苯氧胺合用对人乳腺癌细胞MCF-7生长及ER表达影响[J].2005,(9).
- [2]Cheung KL.Endocrine therapy for breast cancer: an overview.[J].2007,16(4).
- [3]Hiscox S,Barrett Lee P,Davies EL.Aromatase inhibitors in breast cancer.[J].2009,63(4).
- [4]Li PP,Zhang Y.Shu-Gan-Liang-Xue Decoction, a Chinese herbal formula, down-regulates the expression of steroid sulfatase genes in human breast carcinoma MCF-7 cells.[J].2010,127(3).
- [5]Choo MK,Yeo H,Zayzafoon M.NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differentiation.[J].2009,45(3).
- [6]Hamdy RC.Fracture risk assessment in postmenopausal women.[J].2010,11(4).
- [7]Coelho MJ,Fernandes MH.Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation.[J].2000,21(11).
- [8]Suthiphongchai T,Charoenphandhu N,Seriwatanachai D,etc.Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.[J].2008,42(3).
- [9]Jo, YY,Jeong, JH,Jang, ES,etc.Low molecular weight silk fibroin increases alkaline phosphatase and type I collagen expression in MG63 cells[J].2010,43(1).
- [10]Eghbali Fatourechi G,Khosla S,Sanyal A,etc.Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.[J].2003,111(8).
- [11]Edith A, Perez,Katherine, Weilbaecher.Aromatase inhibitors and bone loss.[J].2006,20.
- [12]Rey JM,Somoza Martin JM,Perez Sayans M,etc.RANK/RANKL/OPG role in distraction osteogenesis.[J].2010,109(5).
- [13]Hadji P.Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.[J].2009,69(1).
- [14]Mouridsen H,Gershanovich M.The role of aromatase inhibitors in the treatment of metastatic breast cancer.[J].2003,30(4 Suppl.14).
- [15]Smith IE,Blohmer JU,Boeddinghaus I,etc.Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.[J].2005,23(22).
- [16]Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.[J].2001,25(4).
- [17]Xing LP,Boyce BF.Functions of RANKL/RANK/OPG in bone modeling and remodeling[J].2008,473(2).
- [18]Horner KC.The effect of sex hormones on bone metabolism of the otic capsule--an overview.[J].2009,252(1/2).
- [19]Tim Mosmann.Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays[J].1983,65(1-2).
- [20]Cuzick J,Baum M,Forbes JF,etc.Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.[J].2008,9(1).
- [21]Li PP,Zhang Y.Evaluation of estrogenic potential of Shu-Gan-Liang-Xue Decoction by dual-luciferase reporter based bioluminescent measurements in vitro.[J].2009,126(2).
- [22]Body JJ,Tubiana-Hulin M,Coleman RE,etc.Practical guidance for the management of aromatase inhibitor-associated bone loss.[J].2008,19(8).
- [23]RICHARD L. THERIAULT,RASHMI K. MURTHY,P.K. MORROW.Bone Biology and the Role of the RANK Ligand Pathway[J].2009,23(Suppl.5).